Make or break for costimulatory blockers
Article Abstract:
Immunomodulator CTLA4-Ig, a soluble protein in which cytotoxic T lymphocyte associated antigen 4(CTLA4) is fused to an immunoglobulin tail was set to be miracle drug for organ transplantation but was delayed in the market launch. The launch of the second generation version of CTLA4 -Ig is released in the market as costimulatory blockers in rheumatoid arthritis.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Stroke treatment - light at the end of the tunnel?
Article Abstract:
Biotechnology firms are moving ahead with new approaches and treatments for ischemic stroke despite the high-profile failures of many stroke drugs in late-stage clinical trials. Firms are pursuing new fibrinolytics to restore blood flow, drugs to protect brain cells from stroke damage and agents to help the brain's natural recovery mechanisms.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Stroke treatment - light at the end of the tunnel? rFactor VIII deficit questioned. Protein C may be sepsis solution
- Abstracts: Bouncing back from birthday blues. Taking the ego out of selling. All change for indices
- Abstracts: The ghost of Fawlty Towers. Service with a smile (and with a certificate). Leisure, hotels
- Abstracts: Get ready for consolidation among the regionals. Regionals play to their strengths. Breweries, beverages, pubs, restaurants
- Abstracts: Plenty of value for choosy investors. Value remains. Virtues of value